SOTB07

SOTB07 is a small molecule drug that was developed by SK Chemicals for the treatment of immune system and respiratory diseases, with a primary focus on persistent asthma. It reached Phase 3 clinical trials but development has since been discontinued. The drug was investigated in multi-center, randomized, double-blind, placebo-controlled studies to assess its efficacy and safety in asthma patients. While the precise mechanism of action and molecular target are not publicly disclosed in available sources as of June 2025, it is classified as a small molecule intended for oral administration targeting persistent asthma[1][9].